New published data confirms Nemluvio® (nemolizumab) can rapidly relieve itch and improve sleep in as early as two days in both atopic dermatitis and prurigo nodularis Press release
Galderma announces first patient enrollment in study to assess nemolizumab in adults with Chronic Pruritus of Unknown Origin Press release
Galderma opens up new chapter for Sculptra® with MDR certification and new expanded indication for body Press release
ASDS 2025: Compelling new data on Restylane, Sculptra and Relfydess highlight Galderma’s innovative Injectable Aesthetics portfolio and pipeline Press release
Galderma receives U.S. FDA approval for Restylane® Lyft™ for the enhancement of the chin profile Press release
Galderma delivers record net sales of 3.737 billion USD in the first nine months of 2025 and 15.0% year-on-year growth at constant currency, raises full-year guidance Press release
AMWC Dubai: Galderma demonstrates Injectable Aesthetics leadership through updates on its scientific innovations and community education Press release
